EUVIMEDEUVIMED entdecken
Open Access

Platelet mTOR Is a Regulator of Sterile Immunothrombosis

Frederik Denorme iD, Irina Portier iD, Heide Castro, Abigail Ajanel, Yasuhiro Kosaka, Haley Benzon iD, Claudia V De Araujo, Rhonda Souvenir iD, E Dale Abel iD, Andrew S Weyrich, Matthew T Rondina, Robert A Campbell iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2026-04 · 46 (4)

DOI: 10.1161/atvbaha.125.324250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026-04. Verfasst von Frederik Denorme und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Washington University, Saint Louis, MO (F.D., I.P., H.C., A.A., R.A.C.). Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Blood Platelets, Venous Thrombosis, Ischemic Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immunothrombosis entails a tight interplay between thrombotic and inflammatory pathways and plays a pathological role in ischemic stroke and venous thrombosis. mTOR (mechanistic target of rapamycin) is a canonical serine/threonine kinase and is involved in platelet signaling and thrombus stabilization in vitro. Activation of platelet mTOR is upregulated in aging and inflammatory disorders. However, its role in vivo is poorly understood. METHODS: We used mice specifically lacking mTOR in platelets and assessed platelet activation and platelet-leukocyte interactions in response to platelet agonists. In addition, we examined the role of platelet mTOR in models of hemostasis, thrombosis, inflammatory bleeding, and sterile immunothrombosis, including ischemic stroke and venous thrombosis. RESULTS: Platelets lacking mTOR had a small activation defect and had lower procoagulant potential. In the absence of mTOR, activated platelets interacted less with monocytes and neutrophils. In addition, platelet mTOR regulated platelet-mediated neutrophil activation. Platelet cytoplasmic calcium flux was similar in the presence and absence of mTOR, whereas clot retraction was reduced in the absence of platelet mTOR, suggesting a role for mTOR in selectively regulating Rac1 (Ras-related C3 botulinum toxin substrate 1)–dependent pathways involved in sustained platelet function. In vivo, the absence of platelet mTOR did not impact hemostasis, inflammatory bleeding in the lung and skin, or FeCl 3 -induced arterial thrombosis. In contrast, platelet-specific mTOR knockout mice were protected from ischemic stroke brain injury and stasis-induced venous thrombosis due to reduced thrombosis and inflammation. CONCLUSIONS: Platelet mTOR is a critical mediator of sterile immunothrombosis, although it is dispensable for hemostasis in mice. The immunothrombotic-specific effects of mTOR make it an attractive therapeutic target with a good safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesBlood PlateletsVenous ThrombosisIschemic StrokePlatelet ActivationThrombosisBlood CoagulationInflammationAnimalsDisease Models, AnimalMice, KnockoutMice, Inbred C57BLNeutrophilsrac1 GTP-Binding ProteinSignal TransductionMaleNeuropeptidesNeutrophil ActivationClot RetractionCalcium SignalingHemostasis

Stichwörter der Autor:innen

ischemic strokemiceprotein serine-threonine kinasesthromboinflammationvenous thromboembolism

Substanzen

TOR Serine-Threonine KinasesmTOR protein, mouserac1 GTP-Binding ProteinRac1 protein, mouseNeuropeptides

Autor:innen und Institutionen

  • Department of Emergency Medicine, Washington University, Saint Louis, MO (F.D., I.P., H.C., A.A., R.A.C.).
  • Department of Veterinary Sciences, Faculty of Biomedical, Pharmaceutical and Veterinary Sciences, University of Antwerp, Belgium (F.D.).
  • Program in Molecular Medicine (Y.K., H.B., C.V.D.A., M.T.R.), University of Utah, Salt Lake City.
  • Department of Medicine, David Geffen School of Medicine at UCLA (R.S., E.D.A.).
  • Oklahoma Medical Research Foundation, Oklahoma City (A.S.W.).
  • Division of Microbiology and Immunology, Department of Pathology (M.T.R.), University of Utah, Salt Lake City.

ORCID-Profile: Frederik Denorme, Irina Portier, Haley Benzon, Rhonda Souvenir, E Dale Abel, Robert A Campbell

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS

Zitieren

APA

Denorme, F., Portier, I., Castro, H., Ajanel, A., Kosaka, Y., Benzon, H., De Araujo, C. V., Souvenir, R., Abel, E. D., Weyrich, A. S., Rondina, M. T., & Campbell, R. A. (2026). Platelet mTOR Is a Regulator of Sterile Immunothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 46(4). https://doi.org/10.1161/atvbaha.125.324250

Vancouver

Denorme F, Portier I, Castro H, Ajanel A, Kosaka Y, Benzon H, et al. Platelet mTOR Is a Regulator of Sterile Immunothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026;46(4). doi:10.1161/atvbaha.125.324250

BibTeX
@article{Denorme2026,
  author = {Denorme, Frederik and Portier, Irina and Castro, Heide and Ajanel, Abigail and Kosaka, Yasuhiro and Benzon, Haley and De Araujo, Claudia V and Souvenir, Rhonda and Abel, E Dale and Weyrich, Andrew S and Rondina, Matthew T and Campbell, Robert A},
  title = {Platelet mTOR Is a Regulator of Sterile Immunothrombosis},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1161/atvbaha.125.324250}
}
Kostenlos starten →